Background Recently, in advanced non-small cell lung cancer (NSCLC), standard chemotherapy was flanked by biological agents directed against genomic abnormalities, including EGFR and ALK alterations, that significantly improved patient outcome. Despite these achievements, tumour progression almost always occurs and a reassessment of the tumour genetic profile may contribute to modulating the therapeutic regimen. Resampling may provide tissue for additional tests to detect acquired resistance and/or new genetic alterations, but the currently available information is limited. Patients and Methods Histological and genetic reassessments of biopsy or surgical tissue samples from 50 non-squamous NSCLC patients before and after at least one systemic treatment were performed. EGFR, KRAS, BRAF, PIK3CA and HER2 mutations were sequenced, p.T790M was identified with real-time PCR, and ALK and MET genomic alterations by fluorescence in situ hybridization. Results Overall in baseline biopsies, 37/50 (74 %) tumours had genetic alterations, either single (52 %) or multiple (22 %). Among them, 16 were EGFR mutations and 6 ALK rearrangements. In the second tissue sampling, 54 % of cases had additional genomic changes, including newly acquired alterations (81 %) or losses (18 %). The commonest changes were MET amplification and p.T790M mutation. One case had a histological shift from adenocarcinoma to small cell carcinoma. Conclusions The remarkable number of molecular changes following systemic therapy and the genetic complexity of some cases underline the value of histological and molecular re-evaluation of lung cancer to tailor the most appropriate therapy during disease progression.
Introduction
Non-small cell lung cancer (NSCLC) accounts for 80 % of lung cancer diagnoses, and approximately 70 % of patients
Key Points
The knowledge about acquired resistance to targeted therapy in non small cell lung cancer (NSCLC) patients is limited and is mainly focused on the anti-EGFR and ALK specific treatments. The diagnostic approach of performing a rebiopsy at the time of disease progression, although strongly recommended in the context of clinical trials, is not routine practice.
In our series of 50 retrospective non-squamous NSCLC cases a high number of genetic alterations was found both prior (74%) and after (84%) at least one treatment, with a high prevalence (54%) of genomic changes (both losses and acquisitions). Furthermore in one case a histological shift from adenocarcinoma to small cell lung cancer was found.
These results support the clinical utility of re-evaluation of patients with NSCLC along disease progression by means of rebiopsy.
present at baseline with unresectable locally advanced or metastatic disease. In this setting, standard chemotherapy significantly improves patient outcome, but 2-and 5-year survival remain disappointing [1] . From 2004 and onward, genetic alterations have been identified, mainly in the adenocarcinoma subtype, such as sensitizing mutations of the epidermal growth factor receptor (EGFR) and rearrangements of the anaplastic lymphoma kinase (ALK) genes and specific agents directed against these genomic abnormalities significantly extended progression-free survival of treated patients [2] [3] [4] .
Historically, these targeted therapies had been offered to patients with peculiar clinical characteristics (never smokers, females with adenocarcinoma histology) and in this subgroup of patients a second biopsy was more frequently performed. More recently, on the basis of the outcome of phase III studies performed in genotype-defined patients [5] [6] [7] , the systematic search for EGFR sensitizing mutations and ALK rearrangements has been routinely implemented to better understand acquired resistance mechanisms.
Acquired resistance is usually multifactorial and reflects tumour heterogeneity, whereby resistance clones already exist in the tumour at diagnosis and become dominant as drugsensitive cells die or, alternatively, tumours develop an adaptive response with prevailing anti-apoptotic signals. The knowledge on these changes is almost entirely limited to EGFR mutationpositive NSCLCs that harbour the resistance mutation p. Thr790Met (p.T790M) in exon 20, a finding reported at the time of disease progression in approximately 50 % of the cases. More recently, in ALK rearranged tumours, several ALK kinase domain mutations have been identified with only a slight preponderance of the gatekeeper mutation L1196M [8] . No information is currently available about mutational profile changes in patients harbouring other genetic abnormalities and/or treated with cytotoxic chemotherapy alone.
The diagnostic approach of performing a re-biopsy at the time of disease progression, although strongly recommended in the context of clinical trials, is not routine practice because of the lack of effective therapeutic treatments once a specific molecular abnormality is detected.
In the present study we performed histological and genetic reassessments of tumour tissues from 50 patients with nonsquamous NSCLC sampled before and after at least one systemic treatment, in order to determine the potential impact of pathological and genetic changes in re-biopsy specimens.
Materials and Methods

Case Series
Fifty patients with a pathological diagnosis of non-squamous NSCLC and treated at the San Luigi Hospital, University of Turin, from July 2006 to February 2014 were retrospectively selected from pathology archives and considered for the study if formalin-fixed paraffin embedded (FFPE) tumour samples obtained at baseline and at the end of the front-line treatment or the time of disease progression were available. The search for EGFR sensitivity mutations and ALK translocations was performed at the time of the original diagnosis in 28 and 9 cases, respectively.
Patients were grouped into two subgroups: one (n=31) consisting of stage IV tumours and another (n=19) with early (n=5) or locally advanced (n=14) disease (Table 1) . Metastatic disease patients received systemic treatments (cytotoxic chemotherapy or targeted therapies). Conversely, in the other group, one patient received surgery alone, four received surgery followed by adjuvant chemotherapy, ten received neoadjuvant chemotherapy followed by surgery and four sequential chemo-and radiotherapy with curative intent. Follow-up data were available for all patients.
DNA Extraction and Mutational Analysis
One of the pathologists (L.R.) reassessed each tumour sample for adequacy (set at a minimum of 30 % of tumour cells [9] ) according to current recommendations [10] .
Genomic DNA from FFPE tissue samples was extracted and purified using QIAmp DNA FFPE tissue kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions and quantified by spectrophotometry (Eppendorf, Hamburg, Germany), as previously described [9] . All 100 specimens yielded DNA content and quality adequate for mutational testing. Mutational analyses of EGFR (NM_005228) in exon 18 (codon 719 variants), exon 21 (codons 858 and 861 variants) and exon 19 (from codons 746 to 750) were performed using EGFR TKI response (sensitivity) kit (CE-IVD, Diatech, Jesi, Italy) [9] . Furthermore, 100 ng of genomic DNA was used to amplify target regions containing mutational hotspots of KRAS exon 2 (NM_4985.3), PIK3CA exon 10 and 21 (NM_6218.2), HER2 exon 20 (NM_4448.2), ALK exon 22 and 23 (NM_004304) [two genetic changes known to be associated with resistance to crizotinib], and BRAF exon 11 and 15 (NM_004333.4) genes, by means of real-time end-point PCR using a Rotor-Gene Q instrument (Qiagen, Hilden, Germany). The presence of PCR products for each amplimer was detected by melting analysis with a denaturation step from 65°C up to 95°C. Direct sequencing was performed for mutational analysis of genes investigated using a PyroMark Q96 machine (Biotage, Uppsala, Sweden). Pyrosequencing results were further validated by allelic-specific PCR (ARMS) of EGFR exons 18, 19 and 21, as indicated by guidelines [10] and previously described [9] .
All samples were also tested for the presence of the p.T790M mutation in EGFR exon 20 by ARMS, using specific primers. PCR reaction was performed in a 25-μl-volume mixture containing 2× Master Mix (Promega, Madison, USA), 20× EVA Green dye (Biotium, Hayward, CA, USA), 0.4 μM of each primer and 50 ng template. The amplification was carried out under the following conditions: 95°C for 5 min, then 40 cycles of 95°C for 40 s, 57.6°C for 30 s and 72°C for 40 s and a final extension step of 72°C for 5 min, on a Rotor-Gene Q (Qiagen Hilden, Germany) instrument. Amplification was detected by melting analysis (ramping range of 65-95°C with increasing steps of 1°C), corresponding to the presence of the mutation investigated. According to the guidelines [10] , genomic DNA (gDNA) reference standard (Horizon Diagnostics, Cambridge, UK) harbouring the p.T790M mutation at 1.25 % of mutated allele was used as positive control, whereas gDNA reference standard wild type acted as negative control.
Gene Rearrangement/Amplification Assessment by Fluorescence In Situ Hybridization (FISH)
FISH assays to detect ALK rearrangements and MET amplification were performed on 5-μm unstained FFPE tumour tissue sections using the ALK break-apart probe set (Vysis LSI ALK Dual Color break-apart rearrangement probe; Abbott Molecular, USA) and MET probe set (Vysis MET SpectrumRed FISH Probe Kit; Abbott Molecular, USA), according to the manufacturer's instructions. Briefly, the slides were deparaffinized and quenched in 1× saline-sodium citrate (SSC) buffer at 98°C for 15 min, followed by protease digestion with a ready to use protease K solution (0.25 mg/ml, Invitrogen Life Technologies, USA). The ALK and MET probes were hybridized at 37°C for 16 h after co-denaturing at 73°C for 3 min. Stringency wash was conducted at 73°C with 2× SSC-0.3 % NP40 for 2 min. The slides were dehydrated and counterstained with 4,6-diamidino-2-phenylindole (DAPI) II with the anti-fade compound pphenylenediamine. Slides were evaluated with a triple-pass filter microscope (DAPI, Orange, Green) under a ×100 objective lens in oil immersion. ALK FISH-positive cases were defined as those having more than 15 % of nuclei with split signals (isolated red and green signals with a distance corresponding to at least twice the largest signal size) or with a fusion signal and one red signal alone.
All cases with a mean gene copy number of at least 5 were considered MET FISH-positive according to Cappuzzo et al. [11] . Furthermore, the presence of polysomy, both high and low, was evaluated following the UCCC (University of Colorado Cancer Center) criteria [12] and considered MET FISH-negative.
Statistical Analyses
Categorical variables were reported using frequency distribution and summarized as means and range. Association between categorical variables were assessed using Chi-square or Fisher's exact test. Overall survival was calculated from the time of diagnosis to death or last follow-up. The logrank test was used to assess differences between groups. Significance was set at p<0.05; statistical GraphPad software (PRISM 5, San Diego, CA) was used.
Results
Patients' Characteristics
Clinical-pathological characteristics of the series are summarized in Table 1 . For a long period of time (2004-2010) at our hospital genomic analyses were driven by clinical enrichment criteria and this diagnostic strategy explains the median age of 54 years (range 26-72) and the minority of male patients (40 %); 21 patients were never smokers. The initial biopsy was performed on the primary lung lesion in 31 out of 50 patients (62 %), while in 19 (38 %) the tumour sample was obtained from metastatic deposits (8 extramediastinal lymph nodes, 4 mediastinal lymph nodes, 4 pleura, 1 brain, 1 liver, 1 skin). Diagnosis of adenocarcinoma (ADC) was made in 40/50 (80 %) patients (including 2 ADC with an associated sarcomatoid component) and in the remaining 10 (20 %) cases, the diagnosis was NSCLC. Among these 10 cases, a single case in the metastatic group was further immunoprofiled and a diagnosis of BNSCLC, favour ADC^was assigned. All the others belonged to the early/ locally advanced group and were not further subtyped because the histotype was assessed in the surgical specimens. Among the 31 metastatic disease patients, EGFR mutation test at the time of the original diagnosis was performed in 23 cases (7 cases were positive, all treated with EGFR-TKIs) and ALK FISH test in 9 (3 positive, all treated with crizotinib). All the other patients underwent chemotherapy.
Among the 19 patients with early/locally advanced disease, the routine genomic analyses (EGFR mutations and ALK translocation) were less often requested (chi-square p=0.026 for both genomic markers when compared to the metastatic group).
The re-biopsy was performed after a mean time of 17 months (range 3-58) from baseline diagnosis (16 months for both the metastatic and early/locally advanced groups), and tissue specimens were obtained from lung primaries in 29 out of 50 (58 %) tumours, while 21/50 (42 %) were from metastatic sites. After first-line systemic treatment, all but one ADC diagnoses were confirmed, and in this latter case a morphological switch to small cell lung cancer (SCLC) with neuroendocrine features (synaptophysin positive) was detected (Fig. 1) . In those nine early/locally advanced cases diagnosed as NSCLC-NOS at baseline, at the time of the re-evaluation, the surgical samples revealed six ADC, one pleomorphic sarcomatoid carcinoma, one large cell neuroendocrine carcinoma and one adenosquamous carcinoma. In the five cases with stage I/II disease at diagnosis, radiological and endobronchial findings at relapse fully supported the recurrence of the baseline disease and did not indicate the presence of a second primary lung cancer.
Mean follow-up time was of 37 months (range 4-151); in detail, 8/19 (42 %) patients with early/locally advanced and 19/31 (61 %) metastatic disease patients died, with median overall survival (OS) of 57 (range 4-151) and 36 (range 8-65) months (95 % CI 0.19-1.07), respectively.
Molecular Profiling at Baseline
The complete molecular profiling is outlined in Fig. 2 and summarized in Table 2 . Tumour samples harboured either single or multiple genomic changes (at least two genetic Fig. 2 Genomic profiles at baseline and re-evaluation biopsies of patients with metastatic (a) or early/locally advanced (b) disease. ND not done, D done, ADC adenocarcinoma, NSCLC non-small cell lung cancer, NOS not otherwise specified, SCLC small cell lung cancer, Fav favoured, SARC sarcomatoid, ADSQC adenosquamous carcinoma, LCNEC large cell neuroendocrine carcinoma, CDDP cisplatin, Pem pemetrexed, Pazo pazopanib, Gef gefitinib, Crizo crizotinib, Gem gemcitabine, CBP carboplatin, Adv adjiuvant, Neoadv neoadjuvant, Surg surgery, CarboPac carboplatin and paclitaxel, ASA404 vadimezan, Doce docetaxel, RT radiotherapy, WT wild type, MUT mutated, Alt(A) altered with amplification, Alt(R) altered with rearrangement Fig. 1 Histological shift from adenocarcinoma histology (a) to a morphological small cell carcinoma (b), expressing TTF1 and the neuroendocrine marker synaptophysin (inserts). (a, b haematoxylin and eosin, ×200; inserts 3,3′-diaminobenzidine stain, ×100) alterations in the same or in different genes). Twenty-six samples (52 %, 17 metastatic, 9 early/locally advanced) had only one genomic abnormality (9 EGFR, 5 ALK, 3 MET, 6 KRAS, 2 p.T790M and 1 PIK3CA) and 11 (22 %, 7 metastatic, 4 early/locally advanced) had two genetic alterations (7 EGFR with 3 MET, 3 p.T790M and 1 KRAS; 1 ALK with pT790M; 1 MET with PIK3CA and 2 KRAS with p.T790M). The remaining 13 cases (7 in the metastatic and 6 in locally advanced group) were wild type for all tested genetic alterations.
Finally, the biopsy sampling site (primary or metastases) of the tumour at the two sampling times (either the same or different) did not influence the event of genomic changes identified in the two patients group (Table 2 , lower half).
Molecular Profiling of Tumours in the Re-Biopsy at the Time of Tumour Progression or Surgery Following Chemotherapy
At the re-biopsy (Fig. 2) , 22 cases (46 %, 13 metastatic, 9 early/locally advanced) had one genomic change (1 actEGFR, 5 ALK, 6 MET, 6 KRAS, 2 pT790M; 1 PIK3CA and 1 BRAF), while 20 (38 %, 12 metastatic, 8 early/locally Fig. 2 (continued) advanced) had more than one genomic change (15 with two and 5 with three genetic alterations). Among 13 wild-type tumour samples at baseline, eight acquired genomic changes in MET (5 cases), exon 20 EGFR (1 case), BRAF (1 case) and KRAS (2 cases) genes. Overall, a higher level of genetic heterogeneity was observed, specifically, in 27 out of 50 (54 %, 16 metastatic and 11 early/locally advanced) cases either new (22/27, 81 %) or lost (5/27, 18 %) genetic alterations were detected. Among such cases, no new EGFR sensitizing mutations were acquired de novo during disease progression, whereas they were maintained in 14 out of 16 (87 %) positive cases at baseline, being two EGFR mutations lost in exon 19. At the re-biopsy, p.T790M point mutation was lost in two out of five cases and acquired in four other tumour samples.
In the early/locally advanced group p.T790M mutation and MET amplification showed higher amounts of changes: p.T790M mutation was lost in one case and acquired in four cases while MET amplification was acquired in seven cases and maintained in three cases. KRAS and PIK3CA were documented in one case each.
The single case of adenocarcinoma with a histotype switch to SCLC at re-biopsy (after six cycles of cytotoxic cisplatin and pemetrexed-based chemotherapy; patient 14 of Fig. 2a) showed EGFR p.L858R and p.T790M point mutations at baseline but the loss of the p.T790M mutation in the second biopsy (Fig. 1) .
Genetic and Clinical-Pathological Correlations
Either in early/locally advanced or in metastatic tumours the genotype (including any type of EGFR mutations, ALK, MET, PI3K and KRAS) was not associated with smoking habits, or any other of the considered clinical and pathological variables (including sex, age and clinical stage in early/locally advanced cancers, therapy, type and site of samples).
When molecular profiles were dichotomized between those remaining unchanged and those modified at the re-biopsy in both metastatic and early/locally advanced tumours, none of the considered clinical or pathological parameters listed above showed a statistical association. Only a trend was observed for the distribution of sensitizing EGFR mutations between metastatic and early/locally advanced groups at the first biopsy (p=0.06), but not in re-biopsy samples. Moreover, considering correlations between genomic changes and differences in post-progression survival, only the presence of MET amplification in the re-biopsy sample showed a trend to poor prognosis (hazard ratio 0.34, 95 % CI 0.09-1.3; p=0.06) in the metastatic group (data not shown) whereas no differences in post-progression survival were observed when considering all the other genomic changes.
Discussion
We retrospectively reassessed the molecular profiling in selected genes of 50 cases of non-squamous NSCLC that had paired tumour samplings, at the time of diagnosis and of disease progression (or at the time of surgery), as available in the pathology archive of our department. The panel of investigated genes was quite comparable to that investigated by the Lung Cancer Mutation Consortium [13] and in a French National Study [14] . The incidence of mutations in these two EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, MET hepatocyte growth factor receptor, PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, KRAS Kirsten rat sarcoma viral oncogene homologue, BRAF v-raf murine sarcoma viral oncogene homologue B1, HER2 human epidermal growth factor receptor 2, BIO1 first biopsy, BIO2 second biopsy, WT wild-type, ex exon a Parentheses indicate number of cases previously mutated and reverted to WT (see text for details) large studies and in our case-series cannot be compared for several reasons including our limited sample size and the influence of selection factors (i.e. clinical enrichment criteria mainly for EGFR mutation and ALK translocation) that in our centre drove the clinical decision of performing a second biopsy. This explains why 44 % of the cases harboured Bdruggable^molecular alterations (actEGFR and ALK), whereas 30 % of cases showed mutations in genes usually associated with acquired resistance to targeted therapies (namely MET, KRAS, EGFR p.T790M and PIK3CA [13] ). These data support the hypothesis of a primary mechanism of resistance, such as EGFR p.T790M mutation and MET gene copy number alteration, in tumour specimens of patients with no prior exposure to EGFR TKI [15] . In our series, the prevalence of MET FISH-positive cases at baseline (14 %) was in line with Cappuzzo et al. (11.1 %) [11] , but higher than values reported by others [16] (see below). The presence of primary resistance alterations has also been significantly associated with poorer outcome to specific TKI therapies [17, 18] , but it is not definitively proven yet if the presence of these genomic changes influences the therapeutic choice. Recently, the College of American Pathologists, International Association for the Study of Lung Cancer and the Association for Molecular Pathology (CAP/IASLC/AMP) guidelines mandated testing for EGFR mutations and ALK fusions to guide therapy selection with an EGFR or ALK inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests. However, in daily clinical practice and because of past onsite unavailability of molecular testing for some time, as for instance in our series, the primary driver for testing was the never-smoking status. This minimalistic approach definitively underestimates the incidence of oncogene addicted lung cancer at baseline. In our series, 9 out of 22 tumour samples positive for EGFR sensitizing mutations or ALK translocation were detected in former/current smokers. However, the molecular analyses in these nine samples were anyhow lately performed and all the patients received the appropriate therapy, as second or third line, during the course of the disease. In fact, in our series, only 8 patients received matched therapy in the metastatic group (respectively 5 gefitinib and 3 crizotinib alone), whereas none did in the early/locally advanced group in the absence of regulatory indicators for targeted therapies in this disease stage.
The post-treatment assessment of additional tumour tissue revealed several molecular changes (either losses or acquisitions) in 54 % of cases (27/50) compared to the baseline profile, and a change in the histological subtype in 2 % (1/50) of cases. Among the 13 cases that were wild type at baseline, 8 tumours showed either druggable or resistance-related mutations in the re-biopsy samples. The limited set of genes investigated is not representative enough of the complexity of the acquired resistance mechanisms, but further genomic investigations were not feasible because of the limited amounts of tumour tissue available. This further stresses on the one hand the relevance of adequately triaging tissue samples for both diagnostic and molecular purposes and, on the other, the need for highthroughput technologies for comprehensive molecular profiling. This is even more relevant in the advanced disease setting, where limited tissue samples are usually available.
Beyond technical aspects the need for re-biopsy to assess the histological and molecular tumour profile of nonsquamous NSCLC after treatment and/or disease progression is a matter of debate in the perspective of treatment personalization.
While the assumption of the mutual exclusivity between exon 19-21 EGFR and KRAS mutation and ALK translocation was quite evident at baseline similarly to what reported by others [19] , the co-existence of two of these three genetic changes increased at the time of the re-biopsy.
The most frequently acquired genetic alterations were EGFR point mutation p.T790M and MET amplification, in line with the reported main mechanisms of acquired resistance [15, 20] , irrespective of the type of therapy administered.
In this specific context, even if retrospective and in a small and selected number of patients, some unique findings can be extrapolated from the group of tumours with early or locally advanced stage that were mainly treated with cytotoxic chemotherapy. In such a group, excluding the cases with oncogene addiction (3 EGFR mutations and 1 ALK translocation), acquired MET amplification was observed in 7 out of 15 cases. These data differ from literature data and the discrepancy could reflect the highly conflicting results about MET positivity prevalence in NSCLC, ranging from 2 to 20 %, probably due to different methods of analysis and criteria used for FISH scoring [21, 22] . Cappuzzo et al. [11] investigated a series of radically resected NSCLC and reported a MET amplification in approximately 11.1 % of cases. In other studies, the positive rate was much lower (3 %), but the definition of MET highly amplified tumours was limited to those exceeding the mean of 6 gene copy numbers per cell [16, 23] . However, in one of these studies, the authors also found an additional 30 % of cases with MET intermediate or low altered signals; both squamous and nonsquamous treatment-naive NSCLC showed different extents of MET copy number gains of the intermediate or low type, according to the interpretation criteria used [16] , supporting the concept of a complex array of MET changes. The clinical significance of these changes is far from being understood, at least in the intermediate/borderline subgroup, including the role of MET amplification in the crosstalk between the MET/HGF axis and β-catenin signalling, among other pathways [24] .
Concerning EGFR mutations, the p.T790M point mutation was lost in four out of eight cases positive at baseline and was acquired in other eight cases. The significance of these findings remains largely undefined, with a reduced sensitivity to EGFR-TKI therapy in EGFR p.T790M mutated patients at baseline as opposed to a relative indolent disease course when the p.T790M is detected at progression [25] . Among other genetic alterations lost between baseline tumour sampling and the rebiopsy, one actEGFR mutations was lost probably as a result of a clonal selection induced by therapy, as previously proposed by Nguyen [25] , while another patient had a loss of KRAS mutation probably related to the tumour heterogeneity of the different sampling sites (primary versus metastatic tissue).
The mechanisms leading to genomic heterogeneity among samples before and after treatment are still poorly understood. Both tumour heterogeneity and drug-induced selection mechanisms have to be taken into account and probably concur. The comparative analysis of clinical and pathological parameters among stable and unstable genotypes in our series failed to detect any significant correlation, including type of sample (thus excluding technical artefacts due to the amount of tumour cells available), type of therapy and site of the lesion sampled.
In our series, one case (2 %) underwent a histological shift to SCLC, followed by a further subsequent sarcomatoid transformation in a third biopsy (data not shown). Previous case reports described such histological transition in EGFR mutated lung cancers after therapy as a possible mechanism of drug resistance [26] [27] [28] . The molecular bases of SCLC transformation are not clearly understood. The cancer stem cell hypothesis could explain the existence of a pluripotent population of EGFR mutant cancer stem cells that could favour the development of an undifferentiated tumour cell population [29, 30] . In our case of SCLC transformation, the p.T790M mutation was not detected. In a recent sequencing profiling of SCLC [31] , only one case showed the p.T790M mutation, thus confirming the rare occurrence of this resistance mutation in such a histological type known to be resistant to the EGFR targeted therapy.
In conclusion, despite the retrospective nature of the study and the small and selected number of patients tested, both the observed (54 %) remarkable fraction of additional molecular changes between baseline tumour biopsy and that following systemic therapy and the high genetic complexity of individual tumours underline the value of histological and molecular re-evaluation of lung cancer, in order to tailor the most appropriate therapy during disease progression or subsequent to an initial systemic local treatment.
